miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义

Expression of miR-200b-3p and PAK2 in chemotherapy-resistant and sensitive ovarian cancers

目的:探讨化疗耐药和化疗敏感患者卵巢癌组织中miR-200b-3p和PAK2 mRNA的表达水平及其临床意义。方法:采用生物信息学方法结合文献综合分析初步预测miR-200b-3p在卵巢癌组织中的靶基因为PAK2 ,收集山西省肿瘤医院2015—2018年的25例卵巢癌化疗耐药患者组织样本(耐药组)和25例卵巢癌化疗敏感患者组织样本(敏感组),采用实时荧光定量PCR法(qPCR)检测miR-200b-3p和PAK2 mRNA的相对表达量。比较两组患者肿瘤组织中miR-200b-3p和PAK2 mRNA的表达差异,并分析miR-200b-3p、PAK2 mRNA表达水平与上皮性卵巢癌患者临床病理指标的关系。结果:耐药组卵巢癌患者癌组织miR-200b-3p的表达水平显著高于敏感组卵巢癌患者,是敏感组的15.78倍;耐药组卵巢癌患者癌组织PAK2 mRNA的表达水平显著低于敏感组卵巢癌患者,是敏感组的0.03。miR-200b-3p和PAK2 mRNA表达水平呈负相关(r=-0.560,P <0.01)。结论:miR-200b-3p在化疗耐药性卵巢癌组织中过表达,可能是通过靶向调控PAK2 mRNA参与调节化疗耐药和促进卵巢癌转移。

OBJECTIVE: To investigate the expression and clinical significance of miR- 200b- 3p and PAK2 mRNA in chemotherapy- resistant and sensitive ovarian cancers. METHODS: Bioinformatics method combined with comprehensive literature analyses were used to predict the target gene of miR- 200b- 3p as PAK2. From 2015 to 2018,25 tissue samples from patients with chemo-resistant ovarian cancers and 25 from chemo-sensitive ovarian cancers were collected from Shanxi Provincial Cancer Hospital. Relative expression of miR-200b-3p and PAK2 mRNA from the two groups of tissues were detected by using quantitative real-time PCR (qPCR). Their expression levels and clinic-pathological parameters of the two groups of cancer patients were compared. RESULTS:The expression level of miR-200b-3p was 15.78 times and significantly higher in the chemo-resistant ovarian cancer tissues than the sensitive ones. However, the expression level of PAK2 mRNA was 0.03 times and significantly lower in the resistant and in the sensitive tissues. The expression levels of miR-200b-3p and PAK2 mRNA were significantly correlated with the clinical stage and lymph node metastasis of ovarian cancer patients (P<0.05). CONCLUSION:Our data show that over-expression of miR- 200b-3p and regulation of PAK2 mRNA were involved in the expression of chemoresistance and the promotion of ovarian cancer metastasis.